Rhythm Biosciences (ASX: RHY) — Company Overview, News & Financial Data
Rhythm Biosciences is a medical diagnostics company focused on transforming cancer detection and risk assessment through proprietary biomarker and genomic technologies.
Rhythm Biosciences
Rhythm Biosciences is a medical diagnostics company focused on transforming cancer detection and risk assessment through proprietary biomarker and genomic technologies. The company develops simple, blood-based diagnostic tests designed for early detection of cancer when clinical intervention is most effective. Its leading diagnostic technology provides an accessible blood test for detecting colorectal cancer in symptomatic patients, offering an alternative or complement to existing screening modalities. Additionally, its predictive risk platform integrates genomic and clinical data to quantify individual risk across multiple cancer types. Headquartered in Parkville, Victoria, the company advances clinical validation and global commercial partnerships.
Snapshot
Operations
Products and/or services of Rhythm Biosciences
- Colorectal Cancer Diagnostics: Simple blood-based immunoassay designed for early detection of bowel cancer in symptomatic and screening populations, analyzing specific protein biomarkers in blood samples to provide an accessible alternative to conventional screening methods.
- Predictive Risk Assessment: Personalised risk evaluation platform integrating polygenic genomic risk scores with clinical risk factors to quantify individual susceptibility across multiple cancer types and chronic diseases for early targeted diagnostic healthcare intervention.
- Multi-Cancer Diagnostics Pipeline: Biomarker research and development programs aimed at expanding blood-based early detection diagnostic capabilities to additional high-burden malignancies, including breast, lung, cervical, pancreatic, gastric, and prostate cancers across international diagnostic markets.
- Diagnostic Commercialisation and Partnering: Global commercial partnerships, licensing agreements, and international laboratory distribution network expansion aimed at deploying blood-based cancer screening solutions across clinical testing facilities, healthcare systems, and national health screening programs globally.
Rhythm Biosciences executive team
- David AtkinsCEO & Director
- Mark Andrew Licciardo B BusCompany secretary
Latest news about Rhythm Biosciences
Rhythm Biosciences advances NHS assessment for ColoSTAT
AustraliaRhythm Biosciences achieves first commercial ColoSTAT sale
AustraliaRhythm Biosciences taps 4Cyte for ColoSTAT distribution
AustraliaRhythm Biosciences begins commercial deployment of ColoSTAT
AustraliaRhythm Biosciences secures ColoSTAT partnership
AustraliaRhythm Biosciences secures US CancerIQ partnership for geneType
Australia
Recent announcements
What Rhythm Biosciences (RHY) has told the market, newest first.
- ColoSTAT Economic Study - Australian Public Health SavingsPrice sensitive
- Final Director's Interest Notice - Gavin Fox-Smith
Key financials
Reported results for Rhythm Biosciences, in AUD.
- Market cap
- 22.3M
- Revenue (TTM)
- 1.7M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.0
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 85.3K | -7.5M | -5.9M | |
| 3.2M | -3.5M | -3.8M | |
| 1.7M | -6.7M | -6.9M | |
| 3.1M | -11.5M | -8.2M |